Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 3 | 0 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 1 | 6 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 3 | 6 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 3 | 5 |
| 2017 | 4 | 3 | 7 |
| 2018 | 3 | 1 | 4 |
| 2019 | 3 | 3 | 6 |
| 2020 | 6 | 4 | 10 |
| 2021 | 1 | 5 | 6 |
| 2022 | 1 | 7 | 8 |
| 2023 | 1 | 6 | 7 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure. Am J Cardiovasc Drugs. 2024 Jul; 24(4):481-504.
-
Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes. JAMA Netw Open. 2024 Jun 03; 7(6):e2418808.
-
The national financial burden of guideline directed medical therapy for heart failure patients from 2013 to 2021. Curr Probl Cardiol. 2024 Aug; 49(8):102684.
-
Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2024 04 29; 4:CD006257.
-
Understanding Prescribing Practices and Patient Experiences with Renin Angiotensin System Inhibitors Use in Chronic Kidney Disease: A Qualitative Study. Cardiorenal Med. 2024; 14(1):34-44.
-
Trajectories of adherence to ACEI/ARB medications following a motivational interviewing intervention among Medicare Advantage beneficiaries in Texas. Patient Educ Couns. 2024 Feb; 119:108073.
-
How do we define high and low dose intensity of heart failure medications: a scoping review. BMC Cardiovasc Disord. 2023 09 27; 23(1):478.
-
Mortality, Outcomes, Costs, and Use of?Medicines Following a First Heart?Failure?Hospitalization: EVOLUTION HF. JACC Heart Fail. 2023 10; 11(10):1320-1332.
-
Documented Adverse Drug Reactions and Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Chronic Kidney Disease. Am J Nephrol. 2023; 54(3-4):126-135.
-
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out-of-Pocket Costs. J Am Heart Assoc. 2023 04 04; 12(7):e028278.